Exclusive Summary

• UB047 is a fixed-ratio GLP-1/GCG dual agonist with a unique mechanism that demonstrates superior weight loss, especially fat mass reduction over muscle loss, and significant improvements across multiple metabolic indicators (blood glucose, lipids, blood pressure, insulin resistance) compared to GLP-1 monotherapy for obesity.
• The product shows rapid and sustained glycemic control in clinical trials, alongside more comprehensive cardiovascular metabolic protection, including significant improvements in lipids, blood pressure, and insulin sensitivity, surpassing existing GLP-1 drugs.
• UB047 outperforms competitors in terms of gastrointestinal adverse events and hypoglycemia rates, and does not require titration, which will significantly enhance long-term patient adherence and convenience.
• Beyond obesity, UB047 also shows promise for NASH, with a notable reduction in liver fat deposits, laying the groundwork for broad indication expansion with substantial market potential.

Asset Materials

Contact Us for Full Materials